A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9688 in Patients with Chronic Hepatitis B

Trial Profile

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9688 in Patients with Chronic Hepatitis B

Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Jul 2018

At a glance

  • Drugs GS 9688 (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 09 Jul 2018 Planned number of patients changed from 40 to 60.
    • 04 May 2017 Status changed from not yet recruiting to recruiting.
    • 17 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top